WallStSmart

Carlsmed, Inc. Common Stock (CARL)vsVeeva Systems Inc Class A (VEEV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Veeva Systems Inc Class A generates 5781% more annual revenue ($3.32B vs $56.44M). VEEV leads profitability with a 28.4% profit margin vs -57.8%. VEEV earns a higher WallStSmart Score of 71/100 (B).

CARL

Avoid

29

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 8.5
Piotroski: 6/9Altman Z: 1.51

VEEV

Strong Buy

71

out of 100

Grade: B

Growth: 7.3Profit: 8.0Value: 8.0Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CARL.

VEEVUndervalued (+39.5%)

Margin of Safety

+39.5%

Fair Value

$292.60

Current Price

$172.61

$119.99 discount

UndervaluedFair: $292.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CARL2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
58.2%10/10

Revenue surging 58.2% year-over-year

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

VEEV5 strengths · Avg: 9.0/10
Operating MarginProfitability
30.9%10/10

Strong operational efficiency at 30.9%

Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Profit MarginProfitability
28.4%9/10

Keeps 28 of every $100 in revenue as profit

PEG RatioValuation
0.728/10

Growing faster than its price suggests

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Areas to Watch

CARL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Altman Z-ScoreHealth
1.514/10

Distress zone — elevated risk

Market CapQuality
$277.29M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-36.0%2/10

ROE of -36.0% — below average capital efficiency

VEEV2 concerns · Avg: 3.0/10
P/E RatioValuation
28.2x4/10

Moderate valuation

Free Cash FlowQuality
$02/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : CARL

The strongest argument for CARL centers on Revenue Growth, Debt/Equity. Revenue growth of 58.2% demonstrates continued momentum.

Bull Case : VEEV

The strongest argument for VEEV centers on Operating Margin, Debt/Equity, Profit Margin. Profitability is solid with margins at 28.4% and operating margin at 30.9%. Revenue growth of 16.3% demonstrates continued momentum.

Bear Case : CARL

The primary concerns for CARL are EPS Growth, Altman Z-Score, Market Cap.

Bear Case : VEEV

The primary concerns for VEEV are P/E Ratio, Free Cash Flow.

Key Dynamics to Monitor

CARL profiles as a hypergrowth stock while VEEV is a growth play — different risk/reward profiles.

CARL is growing revenue faster at 58.2% — sustainability is the question.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VEEV scores higher overall (71/100 vs 29/100), backed by strong 28.4% margins and 16.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Carlsmed, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Carlsmed, Inc. develops and operates a surgical platform for the treatment of complex adult spinal deformities that enables surgeons to harness clinical intelligence, advanced image recognition, and 3D printing technologies. The company is headquartered in Carlsbad, California.

Veeva Systems Inc Class A

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.

Visit Website →

Want to dig deeper into these stocks?